REFERENCES:

1. Nutho B, Mahalapbutr P, Hengphasatporn K, Pattaranggoon NC, Simanon N, Shigeta Y, et al. Why are lopinavir and ritonavir effective against the newly emerged coronavirus 2019? Atomistic insights into the inhibitory mechanisms. Biochemistry. 2020 May 12;59(18):1769–79.
2. SYSTEMATIC REVIEWS Lopinavir/ritonavir for COVID-19: A living systematic review-Medwave[Internet].Availablefromhttp://viejo.medwave.cl/link.cgi/English/Original/SystReviews/7966.act…
3. Lopinavir/ritonavir: Repurposing an old drug for HIV infection in CO.
4. Kaizer AM, Shapiro NI, Wild J, Brown SM, Cwik BJ, Hart KW, et al. Lopinavir/ritonavir for treatment of non-hospitalized patients with COVID-19: a randomized clinical trial. International Journal of Infectious Diseases. 2023 Mar 1;128:223–9.
5. A Trial of Lopinavir–Ritonavir in Covid-19. New England Journal of Medicine. 2020 May 21;382(21):e68.
6. Hui DS, I Azhar E, Madani TA, Ntoumi F, Kock R, Dar O, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — The latest 2019 novel coronavirus outbreak in Wuhan, China. Vol. 91, International Journal of Infectious Diseases. Elsevier B.V.; 2020. p. 264–6.
7. Negru PA, Radu AF, Vesa CM, Behl T, Abdel-Daim MM, Nechifor AC, et al. Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir. Vol. 147, Biomedicine and Pharmacotherapy. Elsevier Masson s.r.l.; 2022.
8. Pruijssers AJ, George AS, Schäfer A, Leist SR, Gralinksi LE, Dinnon KH, et al. Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice. Cell Rep. 2020 Jul 21;32(3).
9. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the Treatment of Covid-19 — Final Report. New England Journal of Medicine. 2020 Nov 5;383(19):1813–26.
10. Lee TC, McDonald EG, Butler-Laporte G, Harrison LB, Cheng MP, Brophy JM. Remdesivir and systemic corticosteroids for the treatment of COVID-19: A Bayesian re-analysis. International Journal of Infectious Diseases. 2021 Mar 1;104:671–6.
11. Whittington MD, Pearson SD, Rind DM, Campbell JD. The Cost-Effectiveness of Remdesivir for Hospitalized Patients With COVID-19. Available from: www.elsevier.com/locate/jval
12. Maciorowski D, Idrissi SZE, Gupta Y, Medernach BJ, Burns MB, Becker DP, et al. A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-
13. Ritonavir Treatments against COVID-19. Vol. 25, SLAS Discovery. SAGE Publications Inc.; 2020. p. 1108–22.
14. Lee TC, Murthy S, Del Corpo O, Senécal J, Butler-Laporte G, Sohani ZN, et al. Remdesivir for the treatment of COVID-19: a systematic review and meta-analysis. Vol. 28, Clinical Microbiology and Infection. Elsevier B.V.; 2022. p. 1203–10.
15. Chhatwal J, Basu A. Cost-Effectiveness of Remdesivir for COVID-19 Treatment: What Are We Missing? Vol. 25, Value in Health. Elsevier Ltd; 2022. p. 697–8.
16. Budi DS, Pratama NR, Wafa IA, Putra M, Wardhana MP, Wungu CDK. Remdesivir for pregnancy: A systematic review of antiviral therapy for COVID-19. Heliyon. 2022 Jan 1;8(1).
17. Sharma T, Qamar I, Zwarenstein M. How pragmatic are randomized trials of remdesivir and favipiravir for in-hospital treatment of COVID-19: a descriptive methodological review of trial design using the PRECIS-2 framework. Vol. 152, Journal of Clinical Epidemiology. Elsevier Inc.; 2022. p. 193–200.
18. Tumminia A, Romano R, Brugaletta G, Scicali R, Biondi G, Oliveri R, et al. The impact of obesity and dyslipidemia on Remdesivir effectiveness in hospitalized patients with SARS-CoV-2-related pneumonia: An observational study. Nutrition, Metabolism and Cardiovascular Diseases. 2022 Jul 1;32(7):1635–41.
19. Brouqui P, Giraud-Gatineau A, Raoult D. Critical reappraisal of remdesivir investigational trials in COVID-19. Vol. 38, New Microbes and New Infections. Elsevier Ltd; 2020.
20. Halimi V, Daci A, Ridova N, Panovska-Stavridis I, Stevanovic M, Filipce V, et al. The use of remdesivir outside of clinical trials during the COVID-19 pandemic. Vol. 13, Journal of Pharmaceutical Policy and Practice. BioMed Central Ltd; 2020.
21. Chu CM, Cheng VCC, Hung IFN, Wong MML, Chan KH, Chan KS, et al. Role of lopinavir/ritonavir in the treatment of SARS: Initial virological and clinical findings. Thorax. 2004 Mar;59(3):252–6.
22. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Vol. 30, Cell Research. Springer Nature; 2020. p. 269–71.
23. Tashima K, Crofoot G, Tomaka FL, Kakuda TN, Brochot A, Van de Casteele T, et al. Cobicistat-boosted darunavir in HIV-1-infected adults: Week 48 results of a Phase IIIb, open-label single-arm trial. AIDS Res Ther. 2014 Dec 1;11(1).
24. Hoehl S, Rabenau H, Berger A, Kortenbusch M, Cinatl J, Bojkova D, et al. Evidence of SARS-CoV-2 Infection in Returning Travelers from Wuhan, China. New England Journal of Medicine. 2020 Mar 26;382(13):1278–80.
25. Navarro J, Curran A. Profile of once-daily darunavir/cobicistat fixeddose combination for the treatment of HIV/AIDS. Vol. 8, HIV/AIDS – Research and Palliative Care. Dove Medical Press Ltd.; 2016. p. 175–82.
26. Cahn P, Fourie J, Grinsztejn B, Hodder S, Molina JM, Ruxrungtham K, et al. Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients. AIDS. 2011 Apr 24;25(7):929–39.
27. Hui DS, I Azhar E, Madani TA, Ntoumi F, Kock R, Dar O, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — The latest 2019 novel coronavirus outbreak in Wuhan, China. Vol. 91, International Journal of Infectious Diseases. Elsevier B.V.; 2020. p. 264–6.
28. Baden LR, Rubin EJ. Covid-19 — The Search for Effective Therapy. New England Journal of Medicine [Internet]. 2020;382(19):1851–2. Available from: https://doi.org/10.1056/NEJMe2005477
29. De Meyer S, Bojkova D, Cinatl J, Van Damme E, Buyck C, Van Loock M, et al. Lack of antiviral activity of darunavir against SARS-CoV-2. International Journal of Infectious Diseases. 2020 Aug 1;97:7–10.
30. Frommeyer G, Fischer C, Ellermann C, Dechering DG, Kochhäuser S, Lange PS, et al. Additive Proarrhythmic Effect of Combined Treatment with QT-Prolonging Agents. Cardiovasc Toxicol. 2018 Feb 1;18(1):84–90.
31. Darpo B, Karnad DR, Badilini F, Florian J, Garnett CE, Kothari S, et al. Are women more susceptible than men to drug-induced QT prolongation? Concentration-QTc modelling in a phase 1 study with oral rac-sotalol. Br J Clin Pharmacol. 2014 Mar;77(3):522–31.
32. Mason JW. Antimicrobials and QT prolongation. Journal of Antimicrobial Chemotherapy. 2017 May 1;72(5):1272–4.
33. Funck-Brentano C, Salem JE. Chloroquine or hydroxychloroquine for COVID-19: why might they be hazardous? The Lancet. Lancet Publishing Group; 2020.
34. Mehra MR, Desai SS, Ruschitzka F, Patel AN. RETRACTED:Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. The Lancet. Lancet Publishing Group; 2020.
35. 37-Drugs for Treating Protozoan Infections.
36. Vlachos K, Georgopoulos S, Efremidis M, Sideris A, Letsas KP. An update on risk factors for drug-induced arrhythmias. Vol. 9, Expert Review of Clinical Pharmacology. Taylor and Francis Ltd; 2016. p. 117–27.
37. White NJ. Cardiotoxicity of antimalarial drugs [Internet]. 2007. Available from: http://infection.thelancet.comVol
38. Sarganas G, Garbe E, Klimpel A, Hering RC, Bronder E, Haverkamp W. Epidemiology of symptomatic drug-induced long QT syndrome and torsade de pointes in Germany. Europace. 2014 Jan;16(1):101–8.
39. Vlachos K, Georgopoulos S, Efremidis M, Sideris A, Letsas KP. An update on risk factors for drug-induced arrhythmias. Vol. 9, Expert Review of Clinical Pharmacology. Taylor and Francis Ltd; 2016. p. 117–27.
40. 37-Drugs for Treating Protozoan Infections.
41. White NJ. Cardiotoxicity of antimalarial drugs [Internet]. 2007. Available from: http://infection.thelancet.comVol
42. Darpo B, Karnad DR, Badilini F, Florian J, Garnett CE, Kothari S, et al. Are women more susceptible than men to drug-induced QT prolongation? Concentration-QTc modelling in a phase 1 study with oral rac-sotalol. Br J Clin Pharmacol. 2014 Mar;77(3):522–31.
43. Mason JW. Antimicrobials and QT prolongation. Journal of Antimicrobial Chemotherapy. 2017 May 1;72(5):1272–4.
44. Frommeyer G, Fischer C, Ellermann C, Dechering DG, Kochhäuser S, Lange PS, et al. Additive Proarrhythmic Effect of Combined Treatment with QT-Prolonging Agents. Cardiovasc Toxicol. 2018 Feb 1;18(1):84–90.
45. Sarganas G, Garbe E, Klimpel A, Hering RC, Bronder E, Haverkamp W. Epidemiology of symptomatic drug-induced long QT syndrome and torsade de pointes in Germany. Europace. 2014 Jan;16(1):101–8.
46. Mehra MR, Desai SS, Ruschitzka F, Patel AN. RETRACTED:Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. The Lancet. Lancet Publishing Group; 2020.
47. Funck-Brentano C, Salem JE. Chloroquine or hydroxychloroquine for COVID-19: why might they be hazardous? The Lancet. Lancet Publishing Group; 2020.
48. Berendsen BJA, Wegh RS, Essers ML, Stolker AAM, Weigel S. Quantitative trace analysis of a broad range of antiviral drugs in poultry muscle using column-switch liquid chromatography coupled to tandem mass spectrometry. Anal Bioanal Chem. 2012 Feb;402(4):1611–23.
49. Deng L, Li C, Zeng Q, Liu X, Li X, Zhang H, et al. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study. Journal of Infection. 2020 Jul 1;81(1):e1–5.
50. Kons A, Bērziņš A, Krūkle-Bērziņa K, Actiņš A. Characterization and Physicochemical Evaluation of Molecular Complexes Formed Between Umifenovir and Dicarboxylic Acids. Latvian Journal of Chemistry. 2014 Sep 19;52(1–2):28–40.
51. Lian N, Xie H, Lin S, Huang J, Zhao J, Lin Q. Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study. Clinical Microbiology and Infection. 2020 Jul 1;26(7):917–21.
52. Zha L, Li S, Pan L, Tefsen B, Li Y, French N, Chen L, Yang G, Villanueva EV. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). Medical Journal of Australia. 2020 May;212(9):416-20.
53. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497–506.
54. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020; https://doi.org/10.1016/s2213-2600(20)30076-x [Epub ahead of print].
55. Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends 2020; 14: 69–71.
56. Popp M, Stegemann M, Metzendorf MI, Gould S, Kranke P, Meybohm P, Skoetz N, Weibel S. Ivermectin for preventing and treating COVID-19. Cochrane Database of Systematic Reviews. 2021(7).
57. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook/archive/ v6.1
58. Marshall JC, Murthy S, Diaz J, Adhikari NK, Angus DC, Arabi YM, et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases 2020;20(8):e192-7. [DOI: 10.1016/S1473-3099(20)30483-7] [PMID: 32539990]
59. Singh B, Ryan H, Kredo T, Chaplin M, Fletcher T. Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19. Cochrane Database of Systematic Reviews 2021, Issue 2. Art. No: CD013587. [DOI: 10.1002/14651858.CD013587.pub2]
60. Higgins JP, Eldridge S, Li T. Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook/archive/v6.1.
61. Matthay MA, Thompson BT. Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties. The Lancet Respiratory Medicine. 2020 Dec 1;8(12):1170-2.
62. Centers for Disease Control and Prevention. Outbreak of lung injury associated with the use of e-cigarette, or vaping products. Feb 25, 2020. https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severelung-disease.html (accessed Sept 29, 2020).
63. Layden JE, Ghinai I, Pray I, et al. Pulmonary illness related to e-cigarette use in Illinois and Wisconsin—final report. N Engl J Med 2020; 382: 903–16.
64. Foust AM, Winant AJ, Chu WC, Das KM, Phillips GS, Lee EY. Pediatric SARS, H1N1, MERS, EVALI, and now coronavirus disease (COVID-19) pneumonia: what radiologists need to know. AJR Am J Roentgenol 2020; 215: 736–44.
65. Blagev DP, Harris D, Dunn AC, Guidry DW, Grissom CK, Lanspa MJ. Clinical presentation, treatment, and short-term outcomes of lung injury associated with e-cigarettes or vaping: a prospective observational cohort study. Lancet 2019; 394: 2073–83.
66. Shields PG, Song MA, Freudenheim JL, et al. Lipid laden macrophages and electronic cigarettes in healthy adults. EBioMedicine 2020; 60: 102982.
67. Blount BC, Karwowski MP, Shields PG, et al. Vitamin E acetate in bronchoalveolar-lavage fluid associated with EVALI. N Engl J Med 2020; 382: 697–705
68. Toniati P, Piva S, Cattalini M, Garrafa E, Regola F, Castelli F, Franceschini F, Airò P, Bazzani C, Beindorf EA, Berlendis M. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia, Italy. Autoimmunity reviews. 2020 Jul 1;19(7):102568.
69. Grasselli G, Pesenti A, Cecconi M. Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: early experience and forecast during an emergency response. JAMA – J Am Med Assoc 2020. https://doi.org/10.1001/jama.2020.4031 AIFA. https://www.aifa.gov.it/sperimentazioni-cliniche-covid-19.
70. Zamperetti N, Latronico N. Clinical research in critically ill patients: the situation in Italy. Intensive Care Med 2008;34:1330–2. https://doi.org/10.1007/s00134-008- 1096-6
71. Piva S, Filippini M, Turla F, Cattaneo S, Margola A, De Fulviis S, et al. Clinical presentation and initial management of critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Brescia, Italy. J Crit Care 2020;58:29–33. https://doi.org/10.1016/j.jcrc.2020.04.004.
72. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395. https://doi.org/10.1016/S0140-6736(20)30566-3.
73. Lippi G, Plebani M. Laboratory abnormalities in patients with COVID-2019 infection. Clin Chem Lab Med 2020. https://doi.org/10.1515/cclm-2020-0198.
74. Shoenfeld Y. Corona (COVID-19) time musings: our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning. Autoimmun Rev 2020;102538. https://doi.org/10.1016/j.autrev.2020.102538.
75. Lin Z, Niu J, Xu Y, Qin L, Ding J, Zhou L. Clinical efficacy and adverse events of baricitinib treatment for coronavirus disease-2019 (COVID-19): A systematic review and meta-analysis. Journal of Medical Virology. 2022 Apr;94(4):1523-34.
76. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264-269. doi:10.7326/ 0003-4819-151-4-200908180-00135
77. Olivo SA, Macedo LG, Gadotti IC, Fuentes J, Stanton T, Magee DJ. Scales to assess the quality of randomized controlled trials: a systematic review. Phys Ther. 2008;88(2):156-175. doi:10.2522/ptj. 20070147
78. Oremus M, Wolfson C, Perrault A, Demers L, Momoli F, Moride Y. Interrater reliability of the modified Jadad quality scale for systematic reviews of Alzheimer’s disease drug trials. Dement Geriatr Cogn Disord. 2001;12(3):232-236. doi:10.1159/000051263
79. Hasan MJ, Rabbani R, Anam AM, et al. Impact of high dose of baricitinib in severe COVID-19 pneumonia: a prospective cohort study in Bangladesh. BMC Infect Dis. 2021;21(1):427. doi:10.1186/ s12879-021-06119-2
80. Bronte V, Ugel S, Tinazzi E, et al. Baricitinib restrains the immune dysregulation in patients with severe COVID-19. J Clin Invest. 2020; 130(12):6409-6416. doi:10.1172/JCI141772
81. Rodriguez-Garcia JL, Sanchez-Nievas G, Arevalo-Serrano J, Garcia- Gomez C, Jimenez-Vizuete JM, Martinez-Alfaro E. Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study. Rheumatology. 2021;60(1):399-407. doi:10.1093/rheumatology/ keaa587
82. Ioannidis JP, Trikalinos TA. The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey. CMAJ. 2007; 176(8):1091-1096. doi:10.1503/cmaj.060410
83. Lo CK, Mertz D, Loeb M. Newcastle-Ottawa Scale: comparing reviewers’ to authors’ assessments. BMC Med Res Methodol. 2014;14: 45. doi:10.1186/1471-2288-14-45
84. Margulis AV, Pladevall M, Riera-Guardia N, et al. Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastle-Ottawa Scale and the RTI item bank. Clin Epidemiol. 2014;6:359-368. doi:10.2147/CLEP. S66677
85. Guimarães PO, Quirk D, Furtado RH, Maia LN, Saraiva JF, Antunes MO, Kalil Filho R, Junior VM, Soeiro AM, Tognon AP, Veiga VC. Tofacitinib in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine. 2021 Jul 29;385(5):406-15.
86. Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med 2020;383:2255-73.
87. Dowty ME, Lin TH, Jesson MI, et al. Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition. Pharmacol Res Perspect 2019; 7(6):e00537.
88. Boor PPC, de Ruiter PE, Asmawidjaja PS, Lubberts E, van der Laan LJW, Kwekkeboom J. JAK-inhibitor tofacitinib suppresses interferon alfa production by plasmacytoid dendritic cells and inhibits arthrogenic and antiviral effects of interferon alfa. Transl Res 2017;188:67-79
89. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395: 1033-4.
90. Maeshima K, Yamaoka K, Kubo S, et al. The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells. Arthritis Rheum 2012;64: 1790-8.
91. Gadina M, Johnson C, Schwartz D, et al. Translational and clinical advances in JAK-STAT biology: the present and future of jakinibs. J Leukoc Biol 2018;104: 499-514.
92. Fleischmann R, Mysler E, Hall S, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, headto-head, randomised controlled trial. Lancet 2017;390:457-68.
93. Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2017;376:1723-36.
94. Kyriazopoulou E, Panagopoulos P, Metallidis S, Dalekos GN, Poulakou G, Gatselis N, Karakike E, Saridaki M, Loli G, Stefos A, Prasianaki D. An open label trial of anakinra to prevent respiratory failure in COVID-19. Elife. 2021 Mar 8;10:e66125.
95. Barrera CM, Mykietiuk A, Metev H, Nitu MF, Karimjee N, Doreski PA, Mitha I, Tanaseanu CM, Molina JM, Antonovsky Y, Van Rensburg DJ, Rowe BH, Flores-Figueroa J, Rewerska B, Clark K, Keedy K, Sheets A, Scott D,
96. Azam TU, Shadid H, Blakely P, O’Hayer P, Berlin H, Pan M. 2020. Soluble urokinase receptor in COVID-19 related acute kidney injury. Journal of the American Society of Nephrology : JASN 31:2725–2735. DOI: https://doi.org/10.1681/ASN.2020060829
97. Horwith G, Das AF, et al. 2016. Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, activecontrolled, non-inferiority trial (SOLITAIRE-ORAL). The Lancet Infectious Diseases 16:421–430. DOI: https://doi.org/10.1016/S1473-3099(16)00017-7, PMID: 26852726
98. Bleesing J, Prada A, Siegel DM, Villanueva J, Olson J, Ilowite NT, Brunner HI, Griffin T, Graham TB, Sherry DD, Passo MH, Ramanan AV, Filipovich A, Grom AA. 2007. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis & Rheumatism 56:965–971. DOI: https://doi.org/10.1002/art. 22416, PMID: 17328073
99. Cauchois R, Koubi M, Delarbre D, Manet C, Carvelli J, Blasco VB, Jean R, Fouche L, Bornet C, Pauly V, Mazodier K, Pestre V, Jarrot PA, Dinarello CA, Kaplanski G. 2020. Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19. PNAS 117:18951–18953. DOI: https://doi.org/10.1073/pnas. 2009017117, PMID: 32699149
100. Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D, Oltolini C, Castiglioni B, Tassan Din C, Boffini N, Tomelleri A, Farina N, Ruggeri A, Rovere-Querini P, Di Lucca G, Martinenghi S, Scotti R, Tresoldi M, Ciceri F, Landoni G, et al. 2020. Interleukin-1 blockade with high-dose Anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. The Lancet Rheumatology 2:e325–e331. DOI: https://doi.org/10.1016/S2665-9913(20)30127-2, PMID: 32501454
101. Cavalli G, Colafrancesco S, Emmi G, Imazio M, Lopalco G, Maggio MC, Sota J, Dinarello CA. 2021. Interleukin 1a: a comprehensive review on the role of IL-1a in the pathogenesis and treatment of autoimmune and inflammatory diseases. Autoimmunity Reviews 20:102763. DOI: https://doi.org/10.1016/j.autrev.2021.102763, PMID: 33482337